重组抗人CD4单抗(OKT4)流式 | Syd Labs PA007414.h1Fs
重组抗人CD4单克隆抗体，人IgG1 Fc Silent Kappa（克隆号OKT4，Syd Labs货号：PA007414.h1Fs）是用哺乳动物细胞生产的重组抗体，适用于流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）等研究，纯度>95%。其不变区为人Human IgG1 kappa (hIgG1或h1)，可与重组人IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007414.h1Fs |
|---|---|
| 产品名称 | 重组抗人CD4单抗(OKT4)流式 | Syd Labs PA007414.h1Fs |
| 英文名 | Non-conjugated Recombinant Anti-human CD4 Monoclonal Antibody (Clone: OKT4), Human IgG1 Fc Silent Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 分化簇4，leu-3，T4 |
| 概述 | Syd Labs提供重组小鼠IgG2b同型对照抗体和重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | OKT4 |
| 同种型 | 人IgG1 Kappa |
| 特异性 | 该重组 OKT4 抗体与人 CD4 特异性结合 |
| 免疫源 | 抗人CD4单克隆抗体（克隆：OKT4）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，含0.09%叠氮化钠 |
| 偶联 | 非偶联 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 非偶联重组抗人CD4单克隆抗体，人IgG1 Fc Silent Kappa(克隆号OKT4)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 12个月，保存在2 至 8°C。 请勿冻结。 |
| 注意事项 | PA007414.h1Fs Syd Labs提供重组小鼠IgG2b同型对照抗体和重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | 流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）。 |
文献
抗人CD4单克隆抗体(克隆号OKT4)，非偶联重组，人IgG1 Fc Silent Kappa（Non-conjugated Recombinant Anti-human CD4 Monoclonal Antibody (Clone: OKT4), Human IgG1 Fc Silent Kappa，货号：PA007414.h1Fs Syd Labs）
重组OKT4抗体可结合人CD4蛋白（分化群4）。CD4是一种糖蛋白，也是T细胞受体（TCR）的共受体。CD4蛋白表达于多种免疫细胞表面，包括辅助性T细胞、单核细胞、巨噬细胞和树突状细胞。
抗人CD4单抗(OKT4)部分参考文献:
1. Single amino acid substitution in the V3 domain of CD4 is responsible for OKT4 epitope deficiency
Kawamura, N., et al. Immunogenetics. 1991;34(3):208-10. PMID: 1716607
“The OKT4 antibody (anti-human CD4) was used to identify a deficiency in the CD4 epitope in patients with normal CD4+ T cell counts, as detected by other anti-CD4 monoclonal antibodies. This study linked a single amino acid substitution in the V3 domain of CD4 to the OKT4 epitope deficiency, relevant to understanding HIV pathogenesis as CD4 is the HIV receptor.”
2. Surface antigen changes occurring in short-term cultures of activated human T lymphocytes: analysis by flow cytometry
Boylston, A. W., et al. Cell Immunol. 1982 Jul 15;71(1):12-26. PMID: 6183008
“The OKT4 antibody (anti-human CD4) was used in flow cytometry to analyze surface antigen changes in activated T lymphocytes. The study observed a shift in the OKT4:OKT8 ratio from 60:40 to 40:60 in cultured T lymphoblasts, suggesting a possible phenotype change from OKT4+ to OKT8+ cells, while OKT4 expression remained stable.”
3. Reversible alterations in immunoregulatory T cells in smoking. Analysis by monoclonal antibodies and flow cytometry
Ferson, M., et al. Chest. 1982 Nov;82(5):526-9. PMID: 6982152
“The OKT4 antibody (anti-human CD4) was used in flow cytometry to assess T-cell subsets in heavy smokers, revealing a decreased percentage of OKT4+ cells and a reduced OKT4+/OKT8+ ratio. These changes normalized six weeks after smoking cessation, indicating reversible alterations in immunoregulatory T cells linked to smoking.”
4. Quantitative immunofluorescent assay of full-length, recombinant CD4 in solution and mapping of its epitopes
Lyding, J., et al. J Fluoresc. 1991 Jun;1(2):141-6. PMID: 24242964
“The OKT4 antibody (anti-human CD4) was used in a quantitative flow cytometry assay with Simply Cellular microbeads to measure recombinant CD4 antigen levels. The assay, using standard conditions for OKT4 binding and detection, enabled epitope mapping and determination of CD4 oligomerization levels in solution.”
5. Asbestos exposure correlates with alterations in circulating T cell subsets
de Shazo, R. D., et al. Am J Med Sci. 1985 Jan;289(1):1-5. PMID: 3929128
“The OKT4 antibody (anti-human CD4) was used in flow cytometry to assess alterations in circulating T-cell subsets in asbestos-exposed individuals. The study identified changes in CD4+ T-cell populations, suggesting microbial metabolites like ascorbate influence CD4+ T-cell function, with implications for Th17-mediated conditions like Crohn’s disease.”